PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

This study is testing a new drug combination — PEEL-224, vincristine, and temozolomide — in children and young adults with solid tumors that have come back or stopped responding to prior treatment. The focus is on two specific cancers: neuroblastoma (a cancer of nerve tissue) and rhabdomyosarcoma (a cancer of muscle tissue). **You may be eligible if...** - You are between 1 and 18 years old (or up to 30 for neuroblastoma patients) - You have a solid tumor (non-brain) that has relapsed, progressed, or did not respond to at least one prior treatment - Your cancer was confirmed by biopsy at the time of original diagnosis or relapse - You have measurable or evaluable disease on imaging - Tumor tissue samples are available for testing **You may NOT be eligible if...** - Your cancer is in your brain or spinal cord - You have poor organ function (heart, liver, kidneys, lungs, or bone marrow) - You have an active, uncontrolled infection - You have had a stem cell transplant recently - You are pregnant or unwilling to use contraception Talk to your doctor to see if this trial is right for you.